60 completed, 18 unknown, 9 active not recruiting, 8 recruiting. 46 Phase 2, 25 Phase 4, 14 Phase 3, 12 Phase 1, 4 Not applicable.
Follow PETHEMA Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin (IO) - Acute Lymphobkastic Leukemia, Adult | Phase 2 | Not yet recruiting | PETHEMA Foundation | 30 | 2026-10-30 | 2026-10-07 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Azacitidine, Venetoclax, Quizartinib - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | PETHEMA Foundation | 376 | 2026-07-02 | 2026-10-07 |
| Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea - Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Recruiting | PETHEMA Foundation | 50 | 2026-06-12 | 2026-09-22 |
| Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma Belantamab mafodotin, Bortezomib, Dexamethasone - Relapse Multiple Myeloma | Not yet recruiting | PETHEMA Foundation | 100 | 2026-06-01 | 2026-06-24 | |
| Treatment for Ph-negative ALL for Adults up to 65 Years Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL), Transplantation - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | PETHEMA Foundation | 330 | 2026-03-06 | 2026-03-02 |
| Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. Teclistamab, Talquetamab, Daratumumab - Multiple Myeloma (MM) | Phase 2 | Recruiting | European Myeloma Network B.V. | 150 | 2025-12-12 | 2026-04-15 |
| Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) Daratumumab, Isatuximab, Bortezomib - De Novo Multiple Myeloma, Anitocabtagene Autoleucel | Phase 2 | Recruiting | PETHEMA Foundation | 30 | 2025-06-30 | 2025-08-01 |
| Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Group 1: Dara-VRD followed by apheresis and cilta-cel infusion, Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion - High Risk Smoldering Multiple Myeloma | Phase 2 | Recruiting | PETHEMA Foundation | 20 | 2024-09-30 | 2024-10-26 |
| Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Zanubrutinib Oral Product, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | PETHEMA Foundation | 106 | 2024-09-02 | 2026-06-25 |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL Vincristine, Dexamethasone, Imatinib - Lymphoblastic Leukemia, Philadelphia-Positive ALL | Not yet recruiting | PETHEMA Foundation | 150 | 2023-12-25 | 2023-12-19 | |
| Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Elranatamab (PF-06863135) - Multiple Myeloma in Relapse | Phase 2 | Active not recruiting | PETHEMA Foundation | 50 | 2023-11-23 | 2026-06-04 |
| Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma Daratumumab, Bortezomib, Lenalidomide - High-Risk de Novo Multiple Myeloma | Phase 2 | Active not recruiting | PETHEMA Foundation | 30 | 2023-09-21 | 2026-05-11 |
| Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. Iberdomide, Dexamethasone, Daratumumab - Multiple Myeloma | Phase 2 | Active not recruiting | PETHEMA Foundation | 140 | 2022-12-15 | 2026-05-08 |
| NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Bortezomib, Isatuximab, Iberdomide - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | PETHEMA Foundation | 480 | 2022-11-10 | 2026-06-25 |
| Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. Belantamab mafodotin - RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Unknown | PETHEMA Foundation | 170 | 2022-03-24 | 2022-08-05 | |
| Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide Belantamab mafodotin, Carfilzomib, Dexamethasone - Relapsed Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | PETHEMA Foundation | 60 | 2021-12-20 | 2026-05-11 |
| Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT Bortezomib, Daratumumab - Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT) | Unknown | PETHEMA Foundation | 100 | 2021-11-30 | 2022-09-16 | |
| Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Belantamab mafodotin, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | PETHEMA Foundation | 50 | 2021-04-07 | 2026-03-05 |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old Azacitidine, Venetoclax, Quizartinib - Leukemia, Myeloid, Acute, De Novo | Phase 1 / Phase 2 | Completed | PETHEMA Foundation | 113 | 2020-11-04 | 2026-05-13 |
| Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia CPX-351 - Newly Diagnosed Secondary or High Risk AML | Phase 2 | Completed | PETHEMA Foundation | 59 | 2019-12-26 | 2026-06-25 |
Showing 20 of 107. Sign in to see all of them.
Multiple Myeloma (27) · Leukemia, Myeloid, Acute (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Recurrence (6) · Leukemia, Promyelocytic, Acute (3) · Lymphoma (3) · Myelodysplastic Syndromes (3) · Neoplasm, Residual (3) · Burkitt Lymphoma (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Smoldering Multiple Myeloma (2) · Amyloidosis (1) · Aspergillosis (1)
Dexamethasone (26) · Cytarabine (25) · Bortezomib (18) · Lenalidomide (12) · Methotrexate (12) · Prednisone (12) · Vincristine (12) · Idarubicin (11) · fludarabine (10) · Cyclophosphamide (9) · Daunorubicin (8) · Mercaptopurine (7) · daratumumab (7) · Melphalan (6) · Asparaginase (5)
Spain (104) · Italy (1) · Netherlands (1) · Norway (1) · Poland (1) · Portugal (1) · Uruguay (1)
Sanz Miguel Angel, Dr (4) · Pau Montesinos (3) · Sanz Guillermo, Dr (3) · Bastida Pilar, Dr (2) · Javier de la Rubia (2) · Juan Jose Lahuerta, Dr (2)
PMID 24117042, PMID 21160068, PMID 22966847, PMID 34587246, PMID 38023148, PMID 38031761, PMID 38048552, PMID 39293025, PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 18612103, PMID 18669875, PMID 19755674, PMID 19880781, PMID 19901123, PMID 20220063, PMID 20393132, PMID 20473362, PMID 20663944, PMID 20739218, PMID 21148082, PMID 21900193, PMID 22058223, PMID 22331267, PMID 22511492, PMID 22791289, PMID 22889759, PMID 22897964, PMID 23897961, PMID 23902483, PMID 24081577, PMID 24752047, PMID 25102853, PMID 25911554, PMID 25974382, PMID 25975975, PMID 25987659, PMID 26069291, PMID 26160880, PMID 26423795, PMID 26500339, PMID 26561559, PMID 26668134, PMID 26755711, PMID 27056178, PMID 27118453
2005 (8), 2004 (1), 2008 (1), 2009 (1), 2018 (1), 2023 (1)